RWJ-333369

Phase 3Small molecule

SSK Life Science, Inc.

RWJ-333369 is one of 158 small molecule programs targeting Partial Epilepsy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

157

Competitors

Pipeline

Status by Indication[3][1]

Indication

Partial EpilepsyActive, not recruiting

Peripheral NeuropathyActive, not recruiting

SeizureActive, not recruiting

MigraineActive, not recruiting

EpilepsyActive, not recruiting

Partial EpilepsyPhase 2

Active, not recruiting

Peripheral NeuropathyPhase 2

Active, not recruiting

SeizurePhase 3

Active, not recruiting

MigrainePhase 2

Active, not recruiting

EpilepsyPhase 2

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

RWJ-333369

SSK Life Science, Inc.

Phase 3

1 2

Aimovig

Amgen

Preclinical

33 3

Emgality

Eli Lilly

Preclinical

19 4

Vyepti

Lundbeck

Preclinical

12 5

Bayer Aspirin

Bayer

Preclinical

2 6

Savella

AbbVie

Preclinical

2 7

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 8

Botox

RRevance Therapeutics, Inc.

Preclinical

9 9

Cervidil

Pfizer

Preclinical

1 10

Viagra

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seizure4 trials

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

Completed·SSK Life Science, Inc.·Phase 3·NCT00425282·566 enrolled

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

Completed·SSK Life Science, Inc.·Phase 3·NCT00433667·563 enrolled

Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Terminated·SSK Life Science, Inc.·Phase 3·NCT00697762·56 enrolled

Show 1 more trial

Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Completed·SSK Life Science, Inc.·Phase 3·NCT00697918·11 enrolled

Epilepsy2 trials

An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy

Completed·SSK Life Science, Inc.·Phase 2·NCT00210652·47 enrolled

An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy

Completed·SSK Life Science, Inc.·Phase 2·NCT00210522·421 enrolled

Migraine1 trial

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

Completed·SSK Life Science, Inc.·Phase 2·NCT00109083·300 enrolled

Partial Epilepsy1 trial

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

Completed·SSK Life Science, Inc.·Phase 2·NCT00228969

Peripheral Neuropathy1 trial

Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).

Completed·SSK Life Science, Inc.·Phase 2·NCT00501202·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for RWJ-333369. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RWJ-333369 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RWJ-333369. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SK Life Science, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSK Life Science, Inc.

RWJ-333369

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seizure4 trials

Epilepsy2 trials

Migraine1 trial

Partial Epilepsy1 trial

Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News